The present disclosure relates to identification of inhibitors of hepatitis and herpesvirus replication including compounds of the formula: ##STR00001##
wherein the variables are as defined herein. Also provided are methods of treatment using agents so identified.

The present disclosure relates to identification of inhibitors of hepatitis and herpesvirus replication including compounds of the formula: ##STR00001##
wherein the variables are as defined herein. Also provided are methods of treatment using agents so identified.

Provided herein are novel antibacterial compounds of Formula I. The compounds can be made through enzymatic oxidative dimerization in the presence of a suitable organism and one or more metal salts. Pathogenic bacteria exposed to the compound of Formula I do not develop resistance to these compounds even after prolonged exposure. Also provided herein are methods of treating bacterial infections, and method of killing or disinfecting bacteria.

##STR00001##

Provided herein are novel antibacterial compounds of Formula I. The compounds can be made through enzymatic oxidative dimerization in the presence of a suitable organism and one or more metal salts. Pathogenic bacteria exposed to the compound of Formula I do not develop resistance to these compounds even after prolonged exposure. Also provided herein are methods of treating bacterial infections, and method of killing or disinfecting bacteria.

##STR00001##

The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.

The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.

The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.

The disclosure provides a compound of Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as described herein. The disclosure also provides methods for identifying a compound that selectively kills polyploid cells, and methods for killing polyploid tumor cells by administering a compound of Formula Ito a patient in need thereof.

The disclosure provides a compound of Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as described herein. The disclosure also provides methods for identifying a compound that selectively kills polyploid cells, and methods for killing polyploid tumor cells by administering a compound of Formula Ito a patient in need thereof.

A system and method for purifying coenzyme Q.sub.10 are provided. The method includes: passing a CoQ.sub.10-containing crude product through a first chromatographic column to obtain a first CoQ.sub.10-containing intermediate product. The method further includes preparing, based on the first CoQ.sub.10-containing intermediate product, a second CoQ.sub.10-containing intermediate product. The method further includes passing the second CoQ.sub.10-containing intermediate product through a second chromatographic column to obtain a third CoQ.sub.10-containing intermediate product. The method further includes obtaining purified CoQ.sub.10 product by purifying the third CoQ.sub.10-containing intermediate product.